Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy
Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy
06/04/20, 1:24 PM
Location
cambridge
Round Type
series b
Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces the completion of an extension to its Series B financing led by Columbus Venture Partners.
Company Info
Location
cambridge, maryland, united states
Additional Info
A healthy immune system eliminates harmful foreign pathogens, while being tolerant of self-tissues and organs. When the immune system malfunctions, cells (T Cells) attack self-tissues and organs, causing autoimmune disease. Current autoimmune disease therapies suppress the immune system, helping to minimize these self-attacks, but also raise susceptibility to harmful foreign pathogens. Immunomodulation, the process in which the immune system reduces self-attacks while properly reacting to fight foreign pathogens, holds great potential for autoimmune disease therapies.